Elekta recently entered into an acquisition agreement with Nucletron, the world leader in brachytherapy planning and delivery. This week the acquisition has become a reality, with Elekta receiving final approval from the regulatory bodies for the acquisition of Nucletron.

Nucletron is the global market leader in brachytherapy with a reported revenue of €128 million in 2010 and EBITDA of €26 million.

Nucletron will add 1,000 new customers to Elekta’s customer base of more than 5,000. The two companies have highly synergistic product and technology portfolios. The combination will lead to enhanced solutions for customers and patients, and will allow the enlarged group to take mutual advantage of Nucletron’s expertise in brachytherapy combined with Elekta’s global presence, particularly in emerging markets.

Under the terms of the agreement, Elekta will pay cash consideration of €365 million to acquire Nucletron on a cash and debt-free basis. The transaction is now approved by the Board of Directors of both companies.

Here you can find the official Press Release.